CancerDrs

Head and Neck Cancer clinical trials in Pennsylvania

55 actively recruiting head and neck cancer trials at 43 sites across Pennsylvania.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Pennsylvania:
  • Carlisle Regional Cancer Center — Carlisle, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus — Harrisburg, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Pennsylvania:
  • Site 151 — Bensalem, Pennsylvania
  • Site 158 — Philadelphia, Pennsylvania
  • Site 159 — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Pennsylvania:
  • GSK Investigational Site — Philadelphia, Pennsylvania
  • GSK Investigational Site — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Pennsylvania:
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in Pennsylvania:
  • University of Pennsylvania Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Pennsylvania:
  • University of Pennsylvania, Perelman School of Medicine — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • UPMC Altoona — Altoona, Pennsylvania
  • UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Carlisle Regional Cancer Center — Carlisle, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Pennsylvania:
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
  • Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
  • Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Pennsylvania:
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • Saint Vincent Hospital — Erie, Pennsylvania
  • UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
  • IRMC Cancer Center — Indiana, Pennsylvania
  • Jefferson Hospital — Jefferson Hills, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Pennsylvania:
  • Avenzo Therapeutics Recruiting Site — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Pennsylvania:
  • Cancer Care Associates of York (site 206) — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Pennsylvania:
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in Pennsylvania:
  • University of Pennsylvania (Data Collection Only) — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enr…

Sponsor: NATCO Pharma Ltd.
NCT ID: NCT05283226
Sites in Pennsylvania:
  • Salib Oncology — Easton, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Pennsylvania:
  • UPMC Hillman Cancer Center-UPMC ( Site 6904) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Pennsylvania:
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Pennsylvania:
  • University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Pennsylvania:
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05783323
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780111
Sites in Pennsylvania:
  • UPMC Hillman Cancer Center ( Site 1904) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilate…

Sponsor: Fox Chase Cancer Center
NCT ID: NCT05800574
Sites in Pennsylvania:
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →

Showing 25 of 55 trials with sites in Pennsylvania. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27